VERTEX PHARMACEUTICALS INCORPORATED Share Price & Technical Analysis
VRTX · $526.1 (-0.30%)
Healthcare / Biotechnology
$526.1
-0.30%
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF…
Price chart
Seasonality
Oct has 4 positive and 0 negative years (last 5 years shown)
18% return in 2026, 18% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 3% | 6% | -10% | -5% | 5% | 13% | -5% | 13% | -4% | – | – | – | 18% |
| 25 | 15% | 4% | 1% | 5% | -13% | 1% | 3% | -15% | 0% | 8% | 1% | 5% | 15% |
| 24 | 7% | -3% | -1% | -7% | 16% | 3% | 6% | 0% | -6% | 1% | -1% | -14% | 2% |
| 23 | 12% | -10% | 9% | 8% | -5% | 8% | 1% | -1% | -1% | 4% | -3% | 15% | 38% |
| 22 | 11% | -5% | 14% | 4% | 2% | 2% | 0% | 1% | 3% | 6% | 1% | -9% | 30% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$132.43B
P/E ratio
30.41
52W high
$560.3
52W low
$385.9
Volume
2,19,587
Beta
0.32
Related stocks in Healthcare
Eli Lilly And Company
₹1,165
Mckesson Corporation
₹886.5
Frequently asked questions
- What is VERTEX PHARMACEUTICALS INCORPORATED share price today?
- VERTEX PHARMACEUTICALS INCORPORATED (VRTX) last traded around $526.1 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does VRTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for VRTX. Download the app for real-time alerts.
- How can I analyze VERTEX PHARMACEUTICALS INCORPORATED stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.